This is a rare autoimmune disease. It happens when your body's immune system mistakenly attacks a protein called myelin. This protein is important for protecting nerve fibers in your brain and spinal cord. When the immune system attacks it, it can cause serious problems like numbness, weakness, vision loss, and trouble walking. It's often linked to other conditions like optic neuritis or transverse myelitis.
Every report comes from a Lived member, sent anonymously.
Have you tried Solu-Medrol (Methylprednisolone Hemisuccinate) for MOG Antibody Disease?
MOG antibody disease, often shortened to MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease), is a rare autoimmune condition in which the immune system attacks myelin, the protective coating around nerve fibers in the optic nerves, spinal cord and brain. It is defined by antibodies against myelin oligodendrocyte glycoprotein (MOG), a protein on the outer surface of myelin. These attacks cause inflammation that can come on over hours to days and is often severe. What a person notices depends on where the inflammation is. Optic neuritis, inflammation of the nerve that connects the eye to the brain, causes eye pain and blurred or lost vision, sometimes in both eyes. Myelitis, inflammation of the spinal cord, can cause weakness, numbness or tingling in the limbs and problems with bladder, bowel or sexual function. Inflammation in the brain can cause confusion, headache, drowsiness, seizures or trouble with balance. In children this often takes the form of acute disseminated encephalomyelitis (ADEM), a widespread brain inflammation, while adults more often have optic neuritis or myelitis. MOGAD can look like multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD), two other conditions that damage myelin. It is now recognized as a separate disease with its own pattern of attacks, recovery and treatment response, which is why telling them apart matters.
The cause of MOGAD is unknown. It is an autoimmune condition, meaning the immune system mistakenly targets the body's own tissue, but researchers do not yet know why some people start making MOG antibodies. It is not considered an inherited disease. MOGAD can begin at any age but is relatively more common in children and younger adults, and it affects men and women about equally, unlike MS and NMOSD, which are much more common in women. An infection or vaccination in the weeks before the first attack is reported more often than in MS or NMOSD. That timing is an observed association, not proof that the infection or vaccine caused the disease, and most people who have infections or vaccines never develop MOGAD.
Diagnosis rests on two things together: a blood test that finds MOG antibodies, and symptoms and imaging that fit the typical pattern of the disease. The antibody test should use a cell-based assay, a lab method that detects antibodies binding to MOG in its natural shape. Older test types are not reliable for this purpose. A positive result alone does not settle the diagnosis. Low antibody levels can appear in people with other conditions, including MS, so a weakly positive test in someone whose symptoms and scans look more like MS is treated with caution and may be repeated. The reverse problem also happens: antibody levels can fall after steroid treatment or between attacks, so blood is ideally drawn during an attack and before treatment starts. When blood testing is negative but suspicion is high, testing the spinal fluid can help. Magnetic resonance imaging (MRI) scans of the brain, spinal cord and eye sockets show where inflammation is and whether its pattern looks more like MOGAD, MS or NMOSD. A lumbar puncture (spinal tap) and eye tests such as an examination of the optic nerve and visual field may also be done. Testing for aquaporin-4 antibodies, the marker of NMOSD, is usually done at the same time.
Treatment has two goals: calming an attack quickly and, for people whose disease keeps returning, preventing new attacks. There is currently no cure and no medicine approved by the US Food and Drug Administration (FDA) specifically for MOGAD, so treatment is based on expert experience and observational studies rather than large controlled trials. An attack is usually treated promptly with high-dose corticosteroids, such as intravenous methylprednisolone for several days, and most attacks respond well. For a severe attack or one that does not improve with steroids, doctors may add plasma exchange, which filters antibodies out of the blood, or intravenous immunoglobulin (IVIG), an infusion of antibodies pooled from donors that calms the immune response. Because symptoms can return if steroids are stopped quickly, many people take oral steroids that are tapered slowly over weeks to months. About half of people never have a second attack, so long-term treatment is not usually started after a single episode unless it left serious lasting damage, such as major vision loss in one eye. For relapsing disease, options include regular IVIG infusions, immune-suppressing pills such as mycophenolate or azathioprine, and rituximab, an infusion that removes antibody-producing B cells. Rituximab works less reliably in MOGAD than in NMOSD. Each option involves trade-offs in infection risk, how long it takes to work, cost and how it is given. Satralizumab (Enspryng), an injected medicine already approved for NMOSD, reduced relapses in a recent trial in MOGAD and is under FDA review for this use. Correct diagnosis shapes these choices. Several medicines used for MS do not help MOGAD, and interferon beta may make it more active. Rehabilitation, including physical, occupational and vision therapy, helps with recovery, and treating nerve pain, muscle stiffness, bladder problems and mood is part of good care.
Many people recover well from attacks, often completely or nearly completely, even when the attack itself was frightening. Vision frequently returns after optic neuritis. A minority are left with lasting problems, such as reduced vision in one eye, weakness, bladder difficulties or, in children and adults, changes in thinking and concentration. Long-term disability in MOGAD comes mainly from attacks rather than slow steady worsening, which is a key difference from progressive MS. The course varies. Roughly half of people have one attack and no more, while the other half relapse, sometimes within the first year or two, and sometimes when steroids are tapered. Doctors cannot yet reliably predict which course a person will have, although antibody levels that stay positive over time are linked to a higher chance of relapse. Ongoing chronic pain and depression are common after attacks and are worth treating in their own right. Follow-up usually means regular visits with a neurologist, periodic eye examinations, MRI when new symptoms appear, and monitoring of blood counts and infection risk for anyone on long-term immune treatment.
See a doctor promptly if you develop eye pain with blurred or dimming vision, or new weakness, numbness or tingling, especially if symptoms are building over hours to days. If you already have MOGAD, contact your neurology team the same day about new or returning symptoms such as vision changes, limb weakness, double vision or new bladder or bowel problems, even if you are unsure whether it is a relapse, since early treatment helps recovery. Get emergency care for sudden severe vision loss, rapidly worsening weakness or inability to walk, confusion or unusual drowsiness, or a seizure.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with MOG Antibody Disease is like, what's helped you, or ask the community a question.